WELL Health Technologies Corp. and HEALWELL AI Inc. are expanding their multi-year strategic alliance agreement to launch and manage clinical trial sites at WELL clinic locations across Canada. This collaboration leverages WELL's extensive network of over 180 primary and specialty care clinics and HEALWELL's AI and data science capabilities to transform the clinical research landscape.
AI-Driven Clinical Trial Services
This partnership enables HEALWELL AI to offer a vertically integrated service encompassing patient recruitment, clinical trial execution, and data analysis. By incorporating WELL Health Diagnostic Centres (WHDC), the collaboration can utilize specialty care patient data, particularly in cardiology, radiology, sleep medicine, and endocrinology, to enhance research in cardiovascular disease and its comorbidities.
Strategic Benefits of the Partnership
- Increased Access to Clinical Trials: Patients across Canada will have more convenient access to clinical trials through WELL's extensive clinic network. This reach supports recruitment for various clinical trial programs, from common therapeutic areas to specialized conditions.
- Enhanced Efficiency with AI: HEALWELL's AI and data science focus will streamline trial processes, from patient recruitment to data analysis. AI-driven tools will identify eligible participants, predict outcomes, and reduce trial duration by automating data collection and analysis.
- Strengthened Market Position: WELL and HEALWELL aim to establish a unique niche in AI-enhanced clinical trials, positioning themselves as leaders in digital healthcare solutions for research. This will enhance partnerships with pharmaceutical companies and research institutions seeking AI for trial optimization.
- Data-Driven Insights: Operating clinical trials at scale will generate valuable real-world data to inform future healthcare innovations, supporting HEALWELL AI's goal to enhance disease detection and preventative care tools.
Expert Commentary
Dr. Michael Frankel, Chief Medical Officer of WELL, stated, "Launching and managing clinical trial sites at WELL's clinic locations across Canada is a powerful and transformational strategic initiative. This initiative will allow WELL and HEALWELL to capitalize on their combined strengths in healthcare infrastructure and AI technology, potentially transforming the landscape for clinical research."
Dr. Alexander Dobranowski, CEO of HEALWELL, commented, "Patient identification and recruitment for clinical trials has become an increasingly complex challenge... Through our established late stage CRO, Canadian Phase Onward, HEALWELL has already made significant strides in accelerating the recruitment process, but the growing network of WELL clinics is an opportunity for us to execute our plans at scale."
